MAb 1D6 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
MAb 1D6 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed mAb 1D6 in detail.
, Severity-associated cross-reactive anti-sarbecovirus antibody responses in COVID-19 convalescents and isolation of a dual-targeting monoclonal antibody with cross-neutralizing activity, Frontiers in Immunology, doi:10.3389/fimmu.2026.1839618
Background Sarbecoviruses pose a persistent pandemic threat due to their zoonotic potential and high recombination capacity. This study investigated how disease severity influences cross-reactive antibody responses and the isolation of cross-neutralizing monoclonal antibodies. Methods Plasma samples from 67 COVID-19 convalescents (severe, n=17; non-severe, n=50) were compared for cross-reactive antibody responses against seven sarbecovirus spike proteins. Memory B cells were sorted using dual S1/S2 fluorescent probes to isolate monoclonal antibodies. Results Severe convalescents exhibited significantly higher neutralization titers against six animal-derived sarbecoviruses, responses that persisted for up to one year and were further enhanced by vaccination. From dual-targeting B cells, we isolated mAb 1D6, which simultaneously engages the S1 (ACE2-blocking) and S2 (fusion-inhibiting) domains. mAb 1D6 neutralized SARS-CoV-2 (IC50 = 5.708 μg/mL) and pangolin-CoV-GD (IC50 = 14.02 μg/mL). In contrast, antibody 1F2 bound both S1 and S2 across all tested sarbecoviruses but lacked neutralizing activity. Conclusions Severe COVID-19 was associated with broader and more durable cross-sarbecovirus antibody responses. The dual-targeting antibody 1D6 provides proof-of-concept for a cross-neutralization strategy, although its modest potency requires further optimization for therapeutic application.